|1.||Holdich, T A H: 3 articles (09/2002 - 03/2002)|
|2.||Borowicz, Kinga K: 2 articles (08/2007 - 09/2003)|
|3.||McDermott, M: 2 articles (12/2003 - 02/2001)|
|4.||Ross, C A: 2 articles (12/2003 - 11/2001)|
|5.||Alderfer, V: 2 articles (09/2002 - 02/2001)|
|6.||Chadwick, D W: 2 articles (03/2002 - 09/2001)|
|7.||Hutton, J L: 2 articles (01/2002 - 09/2001)|
|8.||Marson, A G: 2 articles (01/2002 - 09/2001)|
|9.||Leach, J P: 2 articles (01/2002 - 09/2001)|
|10.||Parkinson Study Group: 2 articles (10/2001 - 02/2001)|
09/01/1990 - "Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice."
06/01/1992 - "With the hypothesis that activity against NMDLA-elicited seizures might be reflected by transformation to a more active metabolic species, the aim of the present study was to evaluate potential pharmacological effects of the 9 identified metabolites of remacemide which were all found in human and dog urine. "
09/01/2003 - "Remacemide holds promise to serve as neuroprotectant not only in seizures but perhaps in other neurodegenerative conditions in humans as well."
09/01/2002 - "Median nine-day seizure counts were significantly ( P= 0.0327) lower with remacemide hydrochloride than placebo (6.2 vs. 12.8). "
09/01/2002 - "Remacemide hydrochloride showed a significantly ( P= 0.045) longer median time to fourth seizure compared with placebo (6.8 vs. 3.8 days). "
09/01/2002 - "This multicentre, randomised, double-blind, placebo-controlled, parallel-group study investigated the efficacy, safety and pharmacokinetics of remacemide hydrochloride in adult patients ( n= 59) with refractory epilepsy, undergoing reduced or discontinued antiepileptic drug (AED) usage, as part of an evaluation for epilepsy surgery. "
09/01/2002 - "A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment."
03/01/2002 - "Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. "
03/01/2002 - "Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. "
12/01/2000 - "A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy."
|4.||Chorea (Rheumatic Chorea)
|5.||Huntington Disease (Huntington's Disease)
05/01/1996 - "A controlled trial of remacemide hydrochloride in Huntington's disease."
08/14/2001 - "A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease."
01/01/1999 - "A current, NIH-funded trial of remacemide hydrochloride and Coenzyme Q10 in 340 patients with Huntington's disease is described. "
07/15/2008 - "We conducted an analysis of data from the Coenzyme Q10 and Remacemide Evaluation in Huntington's Disease (CARE-HD) clinical trial. "
12/15/2003 - "We measured caudate volumes on pre- and post-treatment MRI scans from 19 patients at two sites who were participating in CARE-HD (Co-enzyme Q10 and Remacemide: Evaluation in Huntington's Disease), a 30-month clinical trial of remacemide and co-enzyme Q(10) in symptomatic patients with HD. "
|1.||Anticonvulsants (Antiepileptic Drugs)
|8.||Cocaine (Cocaine HCl)
|10.||Aspartic Acid (Aspartate)